tiprankstipranks
Trending News
More News >
Arcturus Therapeutics (ARCT)
NASDAQ:ARCT
US Market
Advertisement

Arcturus Therapeutics (ARCT) Stock Forecast & Price Target

Compare
1,806 Followers
See the Price Targets and Ratings of:

ARCT Analyst Ratings

Strong Buy
10Ratings
Strong Buy
9 Buy
1 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Arcturus
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ARCT Stock 12 Month Forecast

Average Price Target

$56.56
▲(222.46% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Arcturus Therapeutics in the last 3 months. The average price target is $56.56 with a high forecast of $140.00 and a low forecast of $18.50. The average price target represents a 222.46% change from the last price of $17.54.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","141":"$141","41.25":"$41.3","74.5":"$74.5","107.75":"$107.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":140,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$140.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":56.56,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$56.56</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$18.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,41.25,74.5,107.75,141],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.3,22.123076923076923,31.946153846153848,41.769230769230774,51.5923076923077,61.415384615384625,71.23846153846154,81.06153846153846,90.88461538461539,100.70769230769231,110.53076923076924,120.35384615384616,130.1769230769231,{"y":140,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.3,15.704615384615385,19.10923076923077,22.513846153846156,25.918461538461543,29.323076923076925,32.72769230769231,36.13230769230769,39.53692307692308,42.94153846153847,46.346153846153854,49.75076923076924,53.15538461538462,{"y":56.56,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.3,12.776923076923078,13.253846153846155,13.730769230769232,14.207692307692309,14.684615384615386,15.161538461538463,15.638461538461538,16.115384615384617,16.592307692307692,17.06923076923077,17.546153846153846,18.02307692307692,{"y":18.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":21.58,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.1,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.25,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.64,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.97,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.97,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.79,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.43,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.5,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.81,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.99,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.3,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$140.00Average Price Target$56.56Lowest Price Target$18.50
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
William Blair Analyst forecast on ARCT
William Blair
William Blair
Buy
Reiterated
08/22/25
Arcturus Therapeutics: Promising Prospects with ARCT-032 and Billion-Dollar Market PotentialWe hosted meetings management of Arcturus Therapeutics, including CEO Joe Payne, CFO of IR Neda Safarzadeh. The meetings were held ahead of the expected interim data readout from the ongoing Phase II LunairCF trial of ARCT-032 (NCT06747858), an inhaled CFTR mRNA-LNP therapeutic, in patients with cystic fibrosis (CF) expected in September. In the full note, we provide our key takeaways from the investor meetings.
Leerink Partners Analyst forecast on ARCT
Leerink Partners
Leerink Partners
$63$54
Buy
207.87%
Upside
Reiterated
08/22/25
Arcturus Therapeutics price target lowered to $54 from $63 at LeerinkArcturus Therapeutics price target lowered to $54 from $63 at Leerink
TR | OpenAI - 4o Analyst forecast on ARCT
TR | OpenAI - 4o
TR | OpenAI - 4o
$15$18.5
Hold
5.47%
Upside
Reiterated
08/19/25
AI Generated ArticleAI Generated Article
Canaccord Genuity Analyst forecast on ARCT
Canaccord Genuity
Canaccord Genuity
$66
Buy
276.28%
Upside
Reiterated
08/13/25
Arcturus Therapeutics: Promising Developments and Strong Financial Health Justify Buy Rating
Citi
$47$49
Buy
179.36%
Upside
Reiterated
08/13/25
Arcturus Therapeutics price target raised to $49 from $47 at CitiArcturus Therapeutics price target raised to $49 from $47 at Citi
Wells Fargo Analyst forecast on ARCT
Wells Fargo
Wells Fargo
$45$42
Buy
139.45%
Upside
Reiterated
08/12/25
Arcturus Therapeutics price target lowered to $42 from $45 at Wells FargoArcturus Therapeutics price target lowered to $42 from $45 at Wells Fargo
Piper Sandler Analyst forecast on ARCT
Piper Sandler
Piper Sandler
$140
Buy
698.18%
Upside
Reiterated
07/11/25
Analysts Offer Insights on Healthcare Companies: Arcturus Therapeutics (NASDAQ: ARCT) and Pharvaris (NASDAQ: PHVS)
Scotiabank Analyst forecast on ARCT
Scotiabank
Scotiabank
$32$35
Buy
99.54%
Upside
Reiterated
07/02/25
Scotiabank Sticks to Its Buy Rating for Arcturus Therapeutics (ARCT)
BTIG
$48
Buy
173.66%
Upside
Reiterated
07/01/25
Positive Outlook for Arcturus Therapeutics: Promising mRNA Technology and Competitive Edge in Urea-Cycle Disorders
Cantor Fitzgerald Analyst forecast on ARCT
Cantor Fitzgerald
Cantor Fitzgerald
Buy
Reiterated
07/01/25
Cantor Fitzgerald Keeps Their Buy Rating on Arcturus Therapeutics (ARCT)
H.C. Wainwright Analyst forecast on ARCT
H.C. Wainwright
H.C. Wainwright
$60
Buy
242.08%
Upside
Reiterated
04/11/25
Arcturus Therapeutics: Buy Rating Backed by Promising Vaccine Development and Strategic Advancements
Guggenheim
$71$45
Buy
156.56%
Upside
Reiterated
04/10/25
Arcturus Therapeutics price target lowered to $45 from $71 at GuggenheimArcturus Therapeutics price target lowered to $45 from $71 at Guggenheim
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
William Blair Analyst forecast on ARCT
William Blair
William Blair
Buy
Reiterated
08/22/25
Arcturus Therapeutics: Promising Prospects with ARCT-032 and Billion-Dollar Market PotentialWe hosted meetings management of Arcturus Therapeutics, including CEO Joe Payne, CFO of IR Neda Safarzadeh. The meetings were held ahead of the expected interim data readout from the ongoing Phase II LunairCF trial of ARCT-032 (NCT06747858), an inhaled CFTR mRNA-LNP therapeutic, in patients with cystic fibrosis (CF) expected in September. In the full note, we provide our key takeaways from the investor meetings.
Leerink Partners Analyst forecast on ARCT
Leerink Partners
Leerink Partners
$63$54
Buy
207.87%
Upside
Reiterated
08/22/25
Arcturus Therapeutics price target lowered to $54 from $63 at LeerinkArcturus Therapeutics price target lowered to $54 from $63 at Leerink
TR | OpenAI - 4o Analyst forecast on ARCT
TR | OpenAI - 4o
TR | OpenAI - 4o
$15$18.5
Hold
5.47%
Upside
Reiterated
08/19/25
AI Generated ArticleAI Generated Article
Canaccord Genuity Analyst forecast on ARCT
Canaccord Genuity
Canaccord Genuity
$66
Buy
276.28%
Upside
Reiterated
08/13/25
Arcturus Therapeutics: Promising Developments and Strong Financial Health Justify Buy Rating
Citi
$47$49
Buy
179.36%
Upside
Reiterated
08/13/25
Arcturus Therapeutics price target raised to $49 from $47 at CitiArcturus Therapeutics price target raised to $49 from $47 at Citi
Wells Fargo Analyst forecast on ARCT
Wells Fargo
Wells Fargo
$45$42
Buy
139.45%
Upside
Reiterated
08/12/25
Arcturus Therapeutics price target lowered to $42 from $45 at Wells FargoArcturus Therapeutics price target lowered to $42 from $45 at Wells Fargo
Piper Sandler Analyst forecast on ARCT
Piper Sandler
Piper Sandler
$140
Buy
698.18%
Upside
Reiterated
07/11/25
Analysts Offer Insights on Healthcare Companies: Arcturus Therapeutics (NASDAQ: ARCT) and Pharvaris (NASDAQ: PHVS)
Scotiabank Analyst forecast on ARCT
Scotiabank
Scotiabank
$32$35
Buy
99.54%
Upside
Reiterated
07/02/25
Scotiabank Sticks to Its Buy Rating for Arcturus Therapeutics (ARCT)
BTIG
$48
Buy
173.66%
Upside
Reiterated
07/01/25
Positive Outlook for Arcturus Therapeutics: Promising mRNA Technology and Competitive Edge in Urea-Cycle Disorders
Cantor Fitzgerald Analyst forecast on ARCT
Cantor Fitzgerald
Cantor Fitzgerald
Buy
Reiterated
07/01/25
Cantor Fitzgerald Keeps Their Buy Rating on Arcturus Therapeutics (ARCT)
H.C. Wainwright Analyst forecast on ARCT
H.C. Wainwright
H.C. Wainwright
$60
Buy
242.08%
Upside
Reiterated
04/11/25
Arcturus Therapeutics: Buy Rating Backed by Promising Vaccine Development and Strategic Advancements
Guggenheim
$71$45
Buy
156.56%
Upside
Reiterated
04/10/25
Arcturus Therapeutics price target lowered to $45 from $71 at GuggenheimArcturus Therapeutics price target lowered to $45 from $71 at Guggenheim
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Arcturus Therapeutics

1 Month
xxx
Success Rate
9/12 ratings generated profit
75%
Average Return
-1.29%
reiterated a xxx
rating 7 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 75.00% of your transactions generating a profit, with an average return of -1.29% per trade.
3 Months
xxx
Success Rate
6/13 ratings generated profit
46%
Average Return
+3.15%
reiterated a xxx
rating 16 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 46.15% of your transactions generating a profit, with an average return of +3.15% per trade.
1 Year
Lili (Aurélie) NsongoLeerink Partners
Success Rate
8/12 ratings generated profit
67%
Average Return
+15.29%
reiterated a buy rating 7 days ago
Copying Lili (Aurélie) Nsongo's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +15.29% per trade.
2 Years
xxx
Success Rate
8/12 ratings generated profit
67%
Average Return
+16.88%
reiterated a xxx
rating 7 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +16.88% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ARCT Analyst Recommendation Trends

Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
15
16
15
16
16
Buy
5
7
8
8
7
Hold
3
8
11
18
15
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
23
31
34
42
38
In the current month, ARCT has received 23 Buy Ratings, 15 Hold Ratings, and 0 Sell Ratings. ARCT average Analyst price target in the past 3 months is 56.56.
Each month's total comprises the sum of three months' worth of ratings.

ARCT Financial Forecast

ARCT Earnings Forecast

Next quarter’s earnings estimate for ARCT is -$0.76 with a range of -$1.66 to -$0.33. The previous quarter’s EPS was -$0.34. ARCT beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.18% of the time in the same period. In the last calendar year ARCT has Outperformed its overall industry.
Next quarter’s earnings estimate for ARCT is -$0.76 with a range of -$1.66 to -$0.33. The previous quarter’s EPS was -$0.34. ARCT beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.18% of the time in the same period. In the last calendar year ARCT has Outperformed its overall industry.

ARCT Sales Forecast

Next quarter’s sales forecast for ARCT is $18.92M with a range of $0.00 to $29.00M. The previous quarter’s sales results were $24.51M. ARCT beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 46.90% of the time in the same period. In the last calendar year ARCT has Outperformed its overall industry.
Next quarter’s sales forecast for ARCT is $18.92M with a range of $0.00 to $29.00M. The previous quarter’s sales results were $24.51M. ARCT beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 46.90% of the time in the same period. In the last calendar year ARCT has Outperformed its overall industry.

ARCT Stock Forecast FAQ

What is ARCT’s average 12-month price target, according to analysts?
Based on analyst ratings, Arcturus Therapeutics’s 12-month average price target is 56.56.
    What is ARCT’s upside potential, based on the analysts’ average price target?
    Arcturus Therapeutics has 222.46% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ARCT a Buy, Sell or Hold?
          Arcturus Therapeutics has a consensus rating of Strong Buy which is based on 9 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Arcturus Therapeutics’s price target?
            The average price target for Arcturus Therapeutics is 56.56. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $140.00 ,the lowest forecast is $18.50. The average price target represents 222.46% Increase from the current price of $17.54.
              What do analysts say about Arcturus Therapeutics?
              Arcturus Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of ARCT?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis